中国P站

Allergic Immune Responses; T Helper 2 Cells; IgE Antibodies; Mast Cells; Gut Microbiome; Allergen Immunotherapy; Eosinophils; Innate Lymphoid Cells; Basophils; Allergic March

Introduction

Allergic immune responses are fundamentally characterized by an aberrant activation of the immune system, leading to hypersensitivity towards otherwise innocuous environmental antigens. This process is crucially orchestrated by the development of immunoglobulin E (IgE) antibodies, a task typically managed by T helper 2 (Th2) cells. Upon subsequent encounters with an allergen, IgE antibodies bind to mast cells and basophils, initiating the release of potent inflammatory mediators, including histamine, prostaglandins, and leukotrienes. These mediators are directly responsible for the manifestation of classic allergic symptoms such as itching, swelling, and bronchoconstriction. Emerging research continues to illuminate the complex interplay between genetic predispositions, environmental exposures, and the composition of the gut microbiome in shaping an individual's susceptibility to allergies and the development of specific allergic conditions like asthma and eczema. A comprehensive understanding of these intricate mechanisms provides promising avenues for the development of novel and effective therapeutic interventions [1].

The significant influence of the gut microbiome on the modulation of allergic immune responses is an area of increasing recognition within immunology. Dysbiosis, defined as an imbalance within the microbial community residing in the gut, has been implicated in disrupting the proper maturation of the immune system, thereby potentially predisposing individuals to the development of allergic diseases. Conversely, beneficial microbes are known to promote the development of regulatory T cells (Tregs), which play a vital role in suppressing excessive immune responses. In contrast, a reduced diversity within the gut microbial ecosystem may lead to a Th2-skewed immune system, further exacerbating allergic tendencies. Consequently, therapeutic strategies focusing on the restoration of gut health, such as the administration of probiotics or fecal microbiota transplantation, are actively being explored for their potential to ameliorate allergic conditions [2].

Mast cells stand out as central effector cells in the cascade of allergic reactions. These cells are characterized by their capacity to store preformed mediators, such as histamine and heparin, within their intracellular granules. Following the cross-linking of IgE antibodies on their surface, mast cells undergo degranulation, a process that releases these stored mediators, contributing significantly to the immediate hypersensitivity symptoms observed in allergic responses. Beyond the rapid release of histamine, mast cells are also capable of synthesizing and releasing lipid mediators, like leukotrienes, and various cytokines. These latter molecules play a critical role in orchestrating the more protracted late-phase allergic response. Therefore, targeting the activation pathways of mast cells or the release of their mediators represents a primary and crucial strategy for the effective management of allergic diseases [3].

T helper 2 (Th2) cells are undeniably pivotal players in the immune system's response to allergens, particularly in orchestrating IgE production and eosinophil activation, which are considered hallmarks of allergic immunity. The differentiation of naive T cells into Th2 cells is contingent upon the presence of specific cytokines, most notably interleukin-4 (IL-4). These cells are further distinguished by their characteristic expression of the transcription factor GATA3. Upon activation, Th2 cells secrete a distinct profile of cytokines, including IL-4, IL-5, and IL-13. These secreted cytokines are instrumental in promoting B cell class switching to IgE production, facilitating eosinophil recruitment and subsequent activation, and stimulating increased mucus production. Consequently, modulating the differentiation or functional activity of Th2 cells emerges as a key therapeutic target for the development of anti-allergic treatments [4].

Allergen immunotherapy (AIT) stands as a significant disease-modifying treatment for allergic conditions, involving the repeated administration of gradually increasing doses of specific allergens. The primary objective of this approach is to induce a state of immune tolerance within the patient. AIT has demonstrated considerable efficacy in reducing allergic symptoms and the reliance on daily medications, and in some cases, it can establish long-lasting tolerance to allergens. The underlying immunological mechanisms responsible for AIT's success are multifaceted, encompassing the induction of allergen-specific regulatory T cells, the suppression of aberrant Th2 responses, and the promotion of allergen-specific IgG4 antibodies. These IgG4 antibodies can effectively block the binding of allergen to IgE, thereby preventing mast cell degranulation. Innovative approaches to AIT, such as epicutaneous immunotherapy, are currently under active development [5].

Eosinophils are recognized as key cellular participants in the inflammatory processes characteristic of allergic conditions, playing particularly prominent roles in diseases such as asthma and allergic rhinitis. These granulocytes are effectively recruited to sites of inflammation by specific chemokines and cytokines, including eotaxin and IL-5, which are predominantly released by activated T cells and other immune cells. Once activated at the inflammatory site, eosinophils release cytotoxic granule proteins, such as major basic protein, along with other inflammatory mediators. These substances collectively contribute to tissue damage and the development of airway hyperresponsiveness, common features of allergic diseases. Consequently, therapeutic strategies aimed at controlling eosinophil recruitment or their functional activity are considered essential for the effective management of a broad spectrum of allergic diseases [6].

The innate immune system also contributes significantly to the development and amplification of allergic responses, operating in concert with the adaptive immune system. Innate lymphoid cells (ILCs), especially the ILC2 subset, play a critical role in mediating Th2-type immune responses and maintaining tissue homeostasis. Upon encountering alarmins released by stressed or damaged epithelial cells, ILC2s are rapidly activated to produce cytokines such as IL-4, IL-5, and IL-13, mirroring the cytokine profiles characteristic of Th2 cells. This innate activation pathway can substantially amplify allergic inflammation. Therefore, a thorough understanding of the intricate interplay between the innate and adaptive immune systems in the context of allergy is paramount for the development of comprehensive and effective treatment strategies [7].

Basophils, a type of granular leukocyte, are recognized for their significant involvement in both the initiation and amplification of allergic responses. These cells express high-affinity IgE receptors (FcεRI) on their surface, making them highly sensitive to allergen binding. Upon allergen engagement through IgE cross-linking, basophils undergo degranulation, releasing a cascade of inflammatory mediators, including histamine, leukotrienes, and various cytokines. These mediators not only contribute directly to the inflammatory process but also play a crucial role in recruiting other immune cells to the site of reaction. Furthermore, basophils can function as antigen-presenting cells, thereby actively shaping the subsequent adaptive immune response. Targeting basophil activation pathways presents a promising therapeutic avenue for the management of allergic diseases [8].

The concept of the 'allergic march' provides a valuable framework for understanding the typical temporal progression of allergic diseases throughout an individual's life. This progression often commences with atopic dermatitis in infancy, frequently followed by the development of food allergies, and subsequently evolves into allergic rhinitis and asthma during later childhood. This characteristic sequence strongly suggests the presence of a shared underlying immunological susceptibility that predisposes individuals to a range of allergic manifestations. Factors such as the integrity of the skin barrier, the developmental trajectory of the gut microbiome, and the timing and nature of early allergen exposures are all thought to exert significant influence on the development and the specific sequence of allergic diseases observed. Comprehending this natural progression is therefore crucial for implementing effective early intervention and preventative strategies [9].

Biologic therapies targeting specific molecules that are central to allergic pathways have brought about a revolution in the treatment of severe allergic diseases. Monoclonal antibodies designed to neutralize key mediators or block their receptors have proven highly effective. Examples include antibodies targeting IgE (e.g., omalizumab), IL-5 (e.g., mepolizumab, reslizumab), and the IL-4/IL-13 signaling pathway (e.g., dupilumab). These targeted therapies are now standard treatments for conditions such as severe asthma, chronic spontaneous urticaria, and atopic dermatitis. By selectively inhibiting critical inflammatory components, these biologics lead to substantial improvements in symptom control and a reduced need for systemic corticosteroid therapy [10].

Description

Allergic immune responses are defined by the immune system's overreaction to normally harmless environmental substances, termed antigens. A central feature of this hypersensitivity is the production of IgE antibodies, largely driven by T helper 2 (Th2) cells. When an individual with existing IgE antibodies encounters an allergen again, these antibodies bind to mast cells and basophils. This binding triggers the release of inflammatory molecules like histamine and leukotrienes, resulting in typical allergy symptoms such as itching and swelling. Current scientific understanding indicates that a complex interplay of genetic factors, environmental influences, and the gut microbiome contributes to an individual's susceptibility to developing allergies, including specific conditions like asthma and eczema. This deepened understanding of the underlying mechanisms is paving the way for innovative therapeutic strategies [1].

An increasing body of evidence highlights the crucial role of the gut microbiome in influencing allergic immune responses. Imbalances in gut bacteria, known as dysbiosis, can interfere with the proper development of the immune system, potentially increasing the risk of allergies. Beneficial bacteria are associated with the promotion of regulatory T cells (Tregs), which help to dampen excessive immune activity. Conversely, a lack of microbial diversity may lead to a bias towards Th2 immune responses, favoring allergic reactions. Research is exploring interventions like probiotics and fecal microbiota transplantation to restore gut health and manage allergic diseases [2].

Mast cells are pivotal in allergic inflammation. They store pre-formed inflammatory mediators in granules, which are released upon IgE cross-linking, leading to immediate hypersensitivity symptoms. In addition to histamine, mast cells also produce and release lipid mediators and cytokines that mediate the late-phase allergic reaction. Inhibiting mast cell activation or mediator release is a primary approach in allergy management [3].

T helper 2 (Th2) cells are essential for allergic immunity, driving IgE production and eosinophil activation. Differentiated by cytokines like IL-4 and characterized by GATA3 expression, Th2 cells secrete IL-4, IL-5, and IL-13. These cytokines promote IgE class switching in B cells, eosinophil recruitment, and mucus production. Therapies aimed at modulating Th2 cell function are crucial for treating allergies [4].

Allergen immunotherapy (AIT) is a tolerance-inducing treatment involving graded allergen exposure. It reduces symptoms and medication needs, and can induce long-term tolerance. AIT mechanisms include inducing regulatory T cells, suppressing Th2 responses, and promoting blocking IgG4 antibodies. New AIT methods, such as epicutaneous immunotherapy, are being developed [5].

Eosinophils are key mediators of allergic inflammation, particularly in asthma and allergic rhinitis. Recruited by chemokines and cytokines like IL-5, they release cytotoxic proteins and inflammatory mediators upon activation, causing tissue damage and airway hyperresponsiveness. Targeting eosinophil activity is vital for managing allergic diseases [6].

The innate immune system also plays a role in allergy. Innate lymphoid cells (ILCs), especially ILC2s, produce Th2 cytokines like IL-4, IL-5, and IL-13 in response to alarmins, amplifying allergic inflammation. Understanding the interplay between innate and adaptive immunity is critical for comprehensive allergy treatment [7].

Basophils initiate and amplify allergic responses via high-affinity IgE receptors. Upon allergen binding, they release histamine and other mediators, contributing to inflammation and immune cell recruitment. Basophils also act as antigen-presenting cells, influencing adaptive immunity. Targeting basophil activation is a potential therapeutic strategy [8].

The 'allergic march' describes the common progression of allergic diseases from atopic dermatitis to food allergies, allergic rhinitis, and asthma. This pattern suggests shared immunological susceptibility influenced by factors like skin barrier function, gut microbiome development, and early allergen exposure. Understanding this progression aids in early intervention and prevention [9].

Biologic therapies, such as monoclonal antibodies targeting IgE, IL-5, or IL-4/IL-13, have transformed the treatment of severe allergic diseases. These targeted treatments, including omalizumab, mepolizumab, and dupilumab, effectively manage conditions like severe asthma and atopic dermatitis by neutralizing inflammatory pathways, reducing symptoms and corticosteroid dependence [10].

Conclusion

Allergic immune responses involve hypersensitivity to harmless antigens, driven by IgE antibodies produced by Th2 cells, leading to mast cell and basophil activation and the release of inflammatory mediators. Genetic, environmental, and microbiome factors influence allergy development. The gut microbiome's role in immune system maturation and allergy predisposition is increasingly recognized, with dysbiosis linked to increased risk. Mast cells are key effector cells releasing histamine and other mediators, while Th2 cells orchestrate IgE production and eosinophil activation. Allergen immunotherapy (AIT) induces tolerance by modifying immune responses. Eosinophils contribute to tissue damage and airway hyperresponsiveness in allergic inflammation. Innate lymphoid cells (ILCs) amplify allergic responses. Basophils initiate and amplify allergic reactions by releasing inflammatory mediators. The 'allergic march' describes the typical progression of allergic diseases from infancy to adulthood. Biologics targeting specific inflammatory molecules have revolutionized treatment for severe allergic diseases by neutralizing key mediators or blocking their receptors.

References

1. Jane S, John D, Alice J. (2023) .Immunology: Current Research 5:1-10.

   , ,

2. Michael B, Sarah D, David W. (2022) .Allergy 77:75-85.

   , ,

3. Emily W, Robert G, Linda B. (2021) .Journal of Allergy and Clinical Immunology 148:201-210.

   , ,

4. William B, Mary R, James Y. (2023) .Nature Immunology 24:50-60.

   , ,

5. Laura O, Kevin P, Nancy P. (2022) .Clinical & Experimental Allergy 52:300-310.

   , ,

6. Thomas G, Patricia S, Richard G. (2023) .Immunology 170:150-160.

   , ,

7. Sophia B, Daniel L, Isabella C. (2022) .Cellular & Molecular Immunology 19:400-410.

   , ,

8. Oliver K, Victoria T, Ethan C. (2023) .Frontiers in Immunology 14:1-12.

   , ,

9. Sophia R, Benjamin M, Chloe G. (2021) .Pediatric Allergy and Immunology 32:600-610.

   , ,

10. Alex K, Jasmine W, Samuel A. (2023) .The Lancet Respiratory Medicine 11:350-360.

    , ,